Company Overview
About Cerevance
Cerevance is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for central nervous system (CNS) diseases. The company's core technological advantage is its NETSseq (Nuclear Enrichment for Transcriptome Sequencing) platform, which profiles gene expression at the individual cell-type level in post-mortem human brain tissue. By identifying transcriptional and epigenetic differences between specific cell types — such as dopaminergic neurons versus medium spiny neurons — Cerevance can discover drug targets that are active in disease-relevant cell populations and largely silent in others, enabling greater target selectivity and potentially better tolerability than broad CNS agents.
Business Model & Competitive Advantage
Cerevance's lead clinical program is CVN424, a highly selective GPR6 inverse agonist developed for Parkinson's disease. GPR6 is selectively expressed in striatal medium spiny neurons — making it an attractive target for improving motor function in Parkinson's with a reduced risk of the side effects associated with dopaminergic drugs. CVN424 completed a Phase 2 clinical trial evaluating its ability to reduce off-time in Parkinson's patients as an adjunct to levodopa. Cerevance has raised over $100M in total funding from investors including Johnson & Johnson Innovation (JJDC), GV (Google Ventures), Lilly Asia Ventures, and Morningside Venture Capital.
Competitive Landscape 2025–2026
The CNS drug discovery landscape is notoriously challenging, with high clinical failure rates driven by poor target validation and inadequate understanding of disease biology in human tissue. Cerevance's NETSseq platform directly addresses this by grounding target selection in human brain biology rather than animal models — a strategy that aligns with the broader industry shift toward human genetics and tissue-based target validation approaches being pursued by companies like Maze Therapeutics and Alector.
Key Differentiators
Emerging Innovator
Cerevance is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Compare Cerevance with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cerevance? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cerevance Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cerevance vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →